YM BioSciences Announces Start of European TheraCIM Trial - EGFr Antibody Trial Initiated in Metastatic Pancreatic Cancer - MISSISSAUGA, ON, Nov...
YM BioSciences reports first quarter operational and financial results MISSISSAUGA, ON, Nov. 15 /CNW/ - YM BioSciences Inc. (TSX:YM, AMEX:YMI...
YM BioSciences reports 2004 year end results MISSISSAUGA, ON, Oct. 21 /CNW/ - YM BioSciences Inc. (TSX:YM, AMEX:YMI, AIM:YMBA), the cancer drug...
YM BioSciences Completes Bought Deal Financing For Gross Proceeds Of $20,795,002 /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION...
RNS Number:5091D YM BioSciences Inc. 30 September 2004 YM BioSciences Completes Bought Deal Financing For Gross Proceeds Of $20,795,002...
YM BioSciences receives approval for American Stock Exchange Listing - Trading on the AMEX(R) to begin on October 1, 2004 under the symbol YMI...
YM BioSciences Files Final Short Form Prospectus /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./...
YM BioSciences Files Preliminary Short Form Prospectus for $20 Million Bought Deal /Not for distribution to U.S. newswire services or...
YM BioSciences Inc. announces exercise of underwriter option to increase bought deal offering size to $20 million /NOT FOR DISTRIBUTION TO U.S...
YM BioSciences Enters Into a Bought Deal Agreement for Gross Proceeds of $13.5 million with an Option to raise up to $20 million /NOT FOR...
YM BioSciences' EGFr antibody receives EU orphan drug designation through Oncoscience AG, its European partner MISSISSAUGA, ON, Aug. 10 /CNW/ - YM...
YM BioSciences Agreement with CancerVax Approved by US Treasury MISSISSAUGA, July 15 /CNW/ - YM BioSciences Inc. (TSX:YM, AIM:YMBA), the cancer...
YM BioSciences Announces First Patient Enrolled in EGFr MAb Trial - Oncosciences initiates first TheraCIM hR3 trial in Paediatric Glioma...
YM BioSciences reports third quarter 2004 results MISSISSAUGA, ON, May 27 /CNW/ - YM BioSciences Inc. (TSX:YM, AIM:YMBA), the cancer drug...
YM BioSciences' Cancer Antibody Subject of Journal Publication - Phase II trial results published for TheraCIM hR3, YM's EGFr MAb - MISSISSAUGA...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.